business

Novo-Backed Biotech Hemab Raises $301.5 Million in Upsized IPO

Bloomberg Markets · Apr 30, 2026, 10:54 PM · Also reported by 4 other sources

Hemab Therapeutics Holdings Inc., a clinical-stage biotechnology company that counts Novo Nordisk Foundation as one of its biggest investors, raised $301.5 million in an upsized US initial public offering that priced at the top of a marketed range.

Read full story on Bloomberg Markets → More top stories

Also covered by

Bloomberg Tech SpaceX Investor 137 Raises $700 Million Ahead of Musk-Led IPO VentureBeat AI Netomi raises $110 million as Accenture and Adobe bet on AI for customer service Fortune Exclusive: Startup Fun raises $72 million for the serious business of converting crypto and cash TechCrunch AI Coby Adcock’s Scout AI raises $100 million to train its models for war. We visited its bootcamp.

Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Novo-Backed Biotech Hemab Raises $301.5 Million in Upsized IPO

Also covered by

More in business